Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Share-based Compensation (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Share-based Compensation data on record, last reported at $303000.0 in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 14.16% year-over-year to $303000.0; the TTM value through Sep 2025 reached $1.6 million, down 8.21%, while the annual FY2024 figure was $1.7 million, 13.0% down from the prior year.
  • Share-based Compensation reached $303000.0 in Q3 2025 per MBRX's latest filing, down from $417000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $979000.0 in Q3 2021 and bottomed at $303000.0 in Q3 2025.
  • Average Share-based Compensation over 5 years is $503315.8, with a median of $493000.0 recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 112.83% in 2021, then dropped 29.47% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $556000.0 in 2021, then fell by 3.78% to $535000.0 in 2022, then decreased by 10.47% to $479000.0 in 2023, then decreased by 10.86% to $427000.0 in 2024, then fell by 29.04% to $303000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $303000.0 in Q3 2025, $417000.0 in Q2 2025, and $485000.0 in Q1 2025.